United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $6.39, $0.14 worse than the analyst estimate of $6.53. Revenue for the quarter came in at $748.9 million versus the consensus estimate of $722.95 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.